New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
20:25 EDTCOCO, COCO, NS, NS, LII, LII, BIP, BIP, NDAQ, NDAQ, LVLT, LVLT, GRA, GRA, CCE, CCE, BEAM, BEAM, RL, RL, MMP, MMP, HUM, HUM, EL, EL, CTSH, CTSH, AGN, AGN, ADP, ADP, TWX, TWX, MRK, MRKNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Merck (MRK), consensus 88c; Time Warner (TWX), consensus $1.15; Automatic Data Processing (ADP), consensus 77c; Allergan (AGN), consensus $1.34; Cognizant (CTSH), consensus $1.06; Estee Lauder (EL), consensus $1.06; Humana (HUM), consensus 94c; Magellan Midstream (MMP), consensus 81c; Ralph Lauren (RL), consensus $2.51; Beam (BEAM), consensus 72c; Coca-Cola Enterprises (CCE), consensus 52c; W.R. Grace (GRA), consensus $1.19; Level 3 (LVLT), consensus 3c; Nasdaq (NDAQ), consensus 67c; Brookfield Infrastructure Partners (BIP), consensus 35c; Lazard (LAZ), consensus 61c; Arrow Electronics(ARW), consensus $1.62; Lennox International (LII), consensus 74c; NuStar Energy (NS), consensus 35c; Corinthian Colleges (COCO), consensus 2c.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 >>
September 28, 2015
05:58 EDTELEstee Lauder initiated with a Hold at Jefferies
Subscribe for More Information
September 27, 2015
19:39 EDTTWX'Hotel Transylvania 2' bites down in record-setting debut
Animated children's film "Hotel Transylvania 2" set a domestic record for September while "Maze Runner" and "Black Mass" dropped in their second weekends at the box office. WEEKEND LEADER: Sony's (SNE) computer animated comedy "Hotel Transylvania 2" grossed $47.5M during its domestic open for the weekend of September 27, beating expectations for $35M-$40M and setting a new record for September box office debuts. Adam Sandler, Selena Gomez, and others returned to provide voice acting for the monster-themed movie, which saw the biggest open yet for Sony Pictures Animation. BOX OFFICE RUNNERS-UP: With Robert DeNiro and Anne Hathaway in leading roles, Time Warner (TWX) subsidiary Warner Bros.' "The Intern" opened at $18.2M against estimates sales of $15M-$20M. Fox's (FOX, FOXA) "Maze Runner: The Scorch Trials" came in third with $14M after grossing $30.3M domestically during last weekend's debut. Meanwhile, Comcast (CMCSA, CMCSK) subsidiary Universal's "Everest" jumped to $13.1M after significantly expanding its screen count, while Warner Bros.' "Black Mass" rounded out this weekend's Top 5 at $11.5M.
16:47 EDTMRKMerck reports Phase 1b data on Keytruda for two gastrointestinal cancers
Subscribe for More Information
14:58 EDTMRKMerck announces Phase 1b data on Keytruda for nasopharyngeal cancer
Subscribe for More Information
September 25, 2015
15:31 EDTMRKMerck volatility elevated as shares trend lower
Merck October weekly call option implied volatility is at 39, October is at 34, November is a 29; compared to its 52-week range of 15 to 34, suggesting large price movement after presidential candidate Hilary Clinton announced plans early this week to cap prescription drug prices.
13:17 EDTTWXFly Watch: 'Hotel Transylvania 2' expected to top weekend box office
Sony's (SNE) animated sequel "'Hotel Transylvania 2," which is opening in 3,600 theaters, is expected to win this weekend's box office with a domestic gross of $35M-$40M. The next bunch of films are all expecting similar grosses in the mid-to-high teens. Time Warner (TWX) subsidiary Warner Bros.' comedy "The Intern," starring Robert DeNiro and Anne Hathaway, is estimated to open in the $15M-$20M range in 3,305 theaters. Comcast (CMCSA, CMCSK) subsidiary Universal's "Everest," which opened last weekend on IMAX (IMAX), is expanding to over 3,000 theaters this weekend and is estimated to gross in the range of $15M-$17M. Fox's (FOX, FOXA) "Maze Runner: The Scorch Trials," which grossed $30.3M domestically for the weekend of September 20, is expected to earn an estimated $16M in its second weekend of release. Warner Bros.' Whitey Bulger biopic "Black Mass," which took in $23.4M in its domestic opening last weekend, is expected to gross $12.5M-$13M this weekend. Additionally, Lions Gate's (LGF) drug cartel drama "Sicario" is playing in about 50 theaters ahead of the film's wide release on October 2.
10:48 EDTTWXMorgan Stanley cautious on media, but sees several stocks punished too hard
Morgan Stanley cut its price targets on a number of media companies, citing the impact of cord cutting and skinny bundles. The firm also reduced its outlook for the pay-TV sector due to its belief that the adoption of skinny bundles will accelerate, while the outlook for cable TV ads has deteriorated slightly, given macro pressures. The firm kept a Cautious view on the media sector, but also identified several stocks in the space that it thinks have been punished too harshly by investors recently. WHAT'S NEW: TV networks in general, and cable networks in particular, have the highest margins in media and are encountering increased top and bottom line competitive pressures, Morgan Stanley analyst Benjamin Swinburne believes. On the top line, they are being hit by ratings and ad pressures as well as cord cutting and distribution consolidation, the analyst stated. Meanwhile, their profit is being hurt by the increased need to obtain new content and intensified competition for content from new sources like Netflix (NFLX) and Google's (GOOG) YouTube, Swinburne said. However, the analyst thinks that media stocks are "starting to get" cheap, given the leverage that many of the companies carry. Swinburne cuts his price target on 21st Century Fox (FOXA) to $31 from $37, on AMC Networks (AMCX) to $86 from $88, on CBS (CBS) to $46 from $56, on Time Warner (TWX) to $72 from $87 and on Viacom (VIAB) to $48 from $60. He kept Overweight ratings on Fox, AMC and CBS, an Equal Weight rating on Time Warner and an Underweight rating on Viacom. OVERDONE DECLINES: Swinburne believes that the declines in three media stocks - CBS, 21st Century Fox, and AMC Networks - have been overdone, while the decline in Comcast's (CMCSA) stock has also been excessive. CBS and 21st Century Fox are "best positioned for the skinny bundle" and have the cheapest valuations relative to their growth rates, Swinburne believes. Meanwhile, AMC Networks has "content momentum" and its EPS can exceed expectations, the analyst believes. Comcast is gaining share in the broadband Internet market, could take share in video soon, and has sufficient scale and offerings to benefit from the increased popularity of skinny bundles, according to the analyst, who kept an Overweight rating on the stock. The media sector could benefit from consolidation going forward, added Swinburne, who recommended that investors interested in buying potential takeover targets in the space focus on AMC Networks, MSG Networks (MSG) and Dreamworks Animation (DWA). He kept Overweight ratings on all three of those stocks. OTHERS TO WATCH: Besides Comcast, other pay TV companies include DISH Network (DISH) and Charter Communications (CHTR). PRICE ACTION: In early trading, Fox A shares lost 0.5% to $25.83, AMC fell 0.3% to $73.29, CBS added 0.2% to $41, Time Warner was little changed at $67.66 and Comcast A shares added 0.6% to $57.17.
08:15 EDTMRKMerck narrow Keytruda label may not matter as much as thought, says Bernstein
Subscribe for More Information
08:00 EDTAGNAllergan launches generic version of INVEGA
Allergan announced that it has launched a generic version of Janssen's INVEGA in the U.S. Allergan is the first company to receive FDA approval for and launch a generic version of INVEGA, demonstrating the deep expertise of the Company's global generics R&D, regulatory and supply chain teams.
06:39 EDTHUMAPA: Big insurance firm mergers could harm mental healthcare, Reuters says
Subscribe for More Information
September 24, 2015
17:04 EDTMRKMerck, Pfizer to collaborate with Agilent's Dako on Avelumab diagnostic
Subscribe for More Information
16:03 EDTMRKNewLink Genetics awarded $8.1M from DTRA to advance Ebola vaccine
NewLink Genetics (NLNK) announced that the Defense Threat Reduction Agency of the Department of Defense has awarded a subsidiary of NewLink Genetics an $8.1M base contract with future options totaling $5.2M to support various development activities of the investigational rVSV-ZEBOV Ebola) vaccine candidate. NewLink has exclusively licensed research, development and manufacturing of the rVSV-ZEBOV vaccine to Merck (MRK). In late 2014, Merck, known as MSD outside the United States and Canada, licensed the vaccine from NewLink Genetics to apply Merck's vaccine expertise to help accelerate the development of this vaccine candidate. Clinical studies of the rVSV-ZEBOV are ongoing.
14:17 EDTAGNAppeals court affirms Shire Vyvanse patents valid until 2023
Subscribe for More Information
10:01 EDTRLOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: 8point3 Energy (CAFD) upgraded to Market Perform from Underperform at Avondale... AEGON (AEG) upgraded to Buy from Neutral at Goldman... AMC Networks (AMCX) upgraded to Buy from Hold at Evercore ISI... Citi ups Ralph Lauren (RL) to Buy on valuation, cost savings... Kate Spade (KATE) upgraded to Overweight from Equal Weight at Stephens... L'Oreal (LRLCY) upgraded to Buy from Hold at Societe Generale... Marriott (MAR) upgraded on historical performance, growth outlook at SunTrust... Monster Beverage (MNST) upgraded to Buy from Neutral at Goldman... Nimble Storage (NMBL) upgraded to Buy from Neutral at Longbow... Qualys (QLYS) upgraded to Neutral from Underperform at Macquarie... Ralph Lauren (RL) upgraded to Buy from Neutral at Citi... Trex Company (TREX) upgraded to Outperform from Neutral at Wedbush... Valero Energy Partners (VLP) upgraded on better than expected transaction at SunTrust.
08:32 EDTRLCiti ups Ralph Lauren to Buy on valuation, cost savings
Citi analyst Kate McShane upgraded Ralph Lauren to Buy from Neutral and lowered her price target for shares to $125 from $134. Shares are trading at their lowest price-to-earnings ratio since mid-2010, McShane tells investors in a research note. Further, the estimated $100M in cost savings from the company's restructuring is likely conservative, the analyst believes. McShane feels new initiatives including Polo Sport, Polo Women's and Chaps could improve Ralph's longer term top-line trends.
07:47 EDTRLRalph Lauren upgraded to Buy from Neutral at Citi
Subscribe for More Information
September 23, 2015
10:44 EDTNDAQChinese Internet stock pullback a buying opportunity, CLSA says
Shares of multiple Chinese Internet companies are down again in morning trading amid more weak economic data from the Asian nation. However, research firm CLSA released a note making favorable comments and evaluations of several of the country's largest Internet players amid the economic slowdown. LITTLE IMPACT FROM SLOWDOWN: After 25 Chinese Internet and telecom companies attended CLSA's Investors' Forum, analyst Elinor Leung stated that Internet companies in China reported that they have been little affected by growing weakness in the nation's economy. Leung said that such companies have attributed their successful performance to a high savings rate, which increases consumer spending power, as well as gains in offline market share. Additionally, companies already listed may benefit from a weak A-share market in China, since smaller companies do not have access to financing and the slow market speeds up consolidation, Leung noted. RATINGS CHANGES: CLSA upgraded online travel service provider Ctrip (CTRP) to Buy from Outperform and maintained an $85 price target on its shares, while also raising its rating on Baidu (BIDU) two notches, to Buy from Underperform. Leung, who lowered Baidu's price target to $180 from $225, said the firm's top sector picks in the country are (JD), Alibaba (BABA), Tencent (TCEHY), and Ctrip. The analyst added that Tencent and Ctrip shares are the "most defensive" stocks, while JD and Alibaba could rebound even more after sentiment improves. WHAT'S NOTABLE: Last Thursday, TechInAsia reported that Baidu chief executive officer Robin Li said that the company was weighing the idea of delisting from the Nasdaq (NDAQ) and re-listing on the A-shares market in China. TechInAsia later added that a spokesperson from the Chinese internet giant "downplayed" the potential move, saying that Li's comments referred to an "unlikely hypothetical situation" in which U.S. investors don't recognize the importance of the online-to-offline market. PRICE ACTION: In morning trading, Baidu shares fell 1.4% to $134.21, Ctrip shares were flat near $66.64, shares slid 2% to $25.04 and Alibaba shares declined 2% to $60.69.
09:05 EDTAGNAmgen and Allergan's lung cancer biosimilar candidate meets Phase 3 endpoints
Subscribe for More Information
08:50 EDTMRKProvectus initiates Phase 1b/2 trial of PV-10 combo with Pembrolizumab
Provectus Biopharmaceuticals (PVCT) announced it has completed development of the protocol for Phase1b/2 testing of its investigational cancer drug PV-10 in combination with pembrolizumab in patients with Stage IV melanoma. Pembrolizumab, also known as Keytruda, a product of Merck (MRK), is an immune checkpoint inhibitor approved for treatment of patients with advanced or unresectable melanoma. PV-10 is Provectus's novel investigational drug for cancer that is injected into solid tumors. It is currently undergoing Phase 3 clinical testing in patients with Stage III melanoma. Clinical testing under the new Phase 1b/2 protocol is expected to commence before the end of the year. The FDA granted accelerated approval to pembrolizumab in September 2014, making it the first FDA-approved anti-PD-1 immune checkpoint inhibitor. Because pembrolizumab is already FDA-approved, Provectus can commence this study with or without assistance of a partner.
08:11 EDTHUMLeerink sees less political risk for Managed Care mergers after hearings
Subscribe for More Information
1 | 2 | 3 | 4 | 5 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use